Hong Kong · Delayed Price · Currency is HKD LongBio Pharma (Suzhou) Statistics
Total Valuation
HKG:1779 has a market cap or net worth of HKD 8.48 billion. The enterprise value is 7.13 billion.
| Market Cap | 8.48B |
| Enterprise Value | 7.13B |
Important Dates
The last earnings date was Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:1779 has 74.19 million shares outstanding. The number of shares has increased by 29.97% in one year.
| Current Share Class | 72.93M |
| Shares Outstanding | 74.19M |
| Shares Change (YoY) | +29.97% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 28.19% |
| Owned by Institutions (%) | 23.11% |
| Float | 30.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,912.60 |
| PB Ratio | 6.52 |
| P/TBV Ratio | 6.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.95, with a Debt / Equity ratio of 0.05.
| Current Ratio | 8.95 |
| Quick Ratio | 8.86 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -180.48 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -19.42% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 30,974 |
| Profits Per Employee | -2.66M |
| Employee Count | 94 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 106.83 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.79 |
| Average Volume (20 Days) | 202,783 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:1779 had revenue of HKD 2.91 million and -249.58 million in losses. Loss per share was -4.04.
| Revenue | 2.91M |
| Gross Profit | 2.91M |
| Operating Income | -254.62M |
| Pretax Income | -249.58M |
| Net Income | -249.58M |
| EBITDA | -250.03M |
| EBIT | -254.62M |
| Loss Per Share | -4.04 |
Balance Sheet
The company has 1.41 billion in cash and 65.03 million in debt, with a net cash position of 1.35 billion or 18.16 per share.
| Cash & Cash Equivalents | 1.41B |
| Total Debt | 65.03M |
| Net Cash | 1.35B |
| Net Cash Per Share | 18.16 |
| Equity (Book Value) | 1.30B |
| Book Value Per Share | 21.00 |
| Working Capital | 1.27B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.64M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -8,744.93% |
| Pretax Margin | -8,571.89% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:1779 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.97% |
| Shareholder Yield | -29.97% |
| Earnings Yield | -2.94% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |